BLISSGVS

Bliss GVS Pharma Share Price

 

 

Invest in Bliss GVS Pharma with 2.38X leverage

Invest with MTF
Bliss GVS Pharma live price: ₹234.18. It opened at ₹230 vs previous close ₹229; intraday high/low: ₹236/₹220. The 50 & 200 DMA stand at ₹204.15/₹173.87.

Bliss GVS Pharma Performance

  • Today's Low
  • ₹220
  • Today's High
  • ₹236
  • 52 Week Low
  • ₹108
  • 52 Week High
  • ₹244
  • Open Price₹230
  • Previous Close₹229
  • Volume2,354,135
  • 50 DMA₹204.15
  • 100 DMA₹189.86
  • 200 DMA₹173.87

Investment Returns

  • Over 1 Month + 10.44%
  • Over 3 Month + 44.46%
  • Over 6 Month + 53.08%
  • Over 1 Year + 96.34%

Smart Investing Starts Here Start SIP with Bliss GVS Pharma for Steady Growth!

Invest Now

Bliss GVS Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 22.7
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 2,477
  • P/B Ratio
  • 2.1
  • Average True Range
  • 13.38
  • EPS
  • 10.46
  • Dividend Yield
  • 0.4
  • MACD Signal
  • 3.19
  • RSI
  • 61.15
  • MFI
  • 68.63

Bliss GVS Pharma Financials

Bliss GVS Pharma Technicals

EMA & SMA

Current Price
₹234.18
+ 4.78 (2.08%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹214.99
  • 50 Day
  • ₹204.15
  • 100 Day
  • ₹189.86
  • 200 Day
  • ₹173.87

Resistance and Support

230.21 Pivot Speed
  • R3 255.97
  • R2 246.06
  • R1 240.12
  • S1 224.27
  • S2 214.36
  • S3 208.42

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bliss GVS Pharma manufactures and exports pharmaceutical products, specializing in suppositories, pessaries, and oral medications. With a global presence in over 60 countries, it serves therapeutic segments like anti-malarial, antibiotics, and dermatology through its state-of-the-art facilities.

Bliss Gvs Pharma has an operating revenue of Rs. 868.11 Cr. on a trailing 12-month basis. An annual revenue growth of 6% is not great, Pre-tax margin of 16% is great, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 13% and 35% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 59 which is a POOR score indicating inconsistency in earnings, a RS Rating of 95 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 26 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Bliss GVS Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-10 Quarterly Results & Interim Dividend
2025-11-06 Quarterly Results
2025-07-29 Quarterly Results
2025-05-12 Audited Results & Final Dividend
2025-01-28 Quarterly Results & Others To consider other business matters. per share(50%)Final Dividend
Date Purpose Remarks
2026-02-18 INTERIM Rs.0.50 per share(50%)Interim Dividend
2025-07-24 FINAL Rs.0.50 per share(50%)Final Dividend
View Bliss GVS Pharma Dividend History Arrow

Bliss GVS Pharma F&O

Bliss GVS Pharma Shareholding Pattern

35.36%
0%
5.78%
14.54%
31.49%
12.83%

Bliss GVS Pharma FAQs

Bliss GVS Pharma share price is ₹234 As on 03 April, 2026 | 01:02

The Market Cap of Bliss GVS Pharma is ₹2477.4 Cr As on 03 April, 2026 | 01:02

The P/E ratio of Bliss GVS Pharma is 22.7 As on 03 April, 2026 | 01:02

The PB ratio of Bliss GVS Pharma is 2.1 As on 03 April, 2026 | 01:02

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23